The field of life sciences research in the United States is changing because of advances in artificial intelligence (AI), especially agentic AI. Agentic AI means AI systems that do more than just help with one simple task—they work on their own to manage many steps, make choices, and organize different workflows. For medical practice administrators, healthcare owners, and IT managers, knowing what agentic AI can do helps explain how it changes clinical trials and improves decisions in life sciences research.
This article looks at how agentic AI changes clinical trial workflows, helps research and clinical work, and how using it in U.S. healthcare can lead to better results for patients and organizations.
Old AI tools mostly automated simple, repeated tasks or helped with data analysis. Agentic AI is more advanced. It can do complicated workflows by using data from many sources, making choices ahead of time, and working with people. In clinical trials, agentic AI can handle things like finding patients, designing trial plans, reviewing data, submitting documents to regulators, and giving advice in real time.
A study by McKinsey & Company showed agentic AI could handle or help with up to 85% of tasks in drug and medical tech work. This includes matching patients, picking trial sites, watching data, and reporting rules. For example, agentic AI looks at patient information to find the best people for trials faster and more accurately than before. This helps shorten trial times, which is very important for healthcare managers in the U.S. because delays can hurt projects and money.
Clinical trials are complicated. They involve many people, strict rules, and lots of data to manage. Agentic AI helps by fixing delays in the workflows through connecting separate data and managing workflows in real time.
In the U.S., healthcare groups have problems because data is spread out. A Salesforce survey found these groups use about 78 different systems. This causes data to be disconnected and slows down teamwork. Agentic AI changes this by making data work together and giving live information.
For admins and IT managers, this means less manual work to handle patient records, legal papers, and trial results. Agentic AI plans work by focusing on the most important tasks and changing plans when trial conditions change, like how many patients join or if there are problems. This helps teams, doctors, and regulators talk better.
IQVIA, a company that leads life sciences AI, works with NVIDIA to create AI agents. These tools use technologies like NIM Agent Blueprints and NeMo Customizer. They make AI models fast to build that help review data, read medical reports, and talk to healthcare workers during trials. Their AI solutions helped trials move faster and cut delays in paperwork, helping trials go from start to market more quickly.
Agentic AI speeds up work and also improves decisions during clinical research. It gives full, real-time analysis of very large and complex data sets that are hard for traditional methods to handle.
AI tools help choose better trial aims, design better plans, and watch trial progress in real time. This lowers risks and raises chances of success in clinics and with regulators. Raja Shankar, VP of Machine Learning at IQVIA, says AI links information across clinical, regulatory, and business areas so decisions are smarter and more reliable.
AI helps researchers quickly review lots of scientific articles, find useful information, and focus on key data for drug development. It also supports predictions that can warn about possible problems like patients leaving or side effects. For clinical admins, this means decisions rely on full evidence, leading to better trial results and faster approvals.
Agentic AI can also make patient involvement easier by simplifying consent forms, sending reminders, and giving ongoing help. This cuts paperwork for healthcare workers, keeps patients involved, and makes sure data is good.
Workflow coordination means managing the many steps in clinical trials. Agentic AI uses many AI agents, each handling a certain job or data analysis, and organizes them to finish workflows well.
Amazon Web Services (AWS) made a Healthcare and Life Sciences Agentic AI toolkit. It has AI agents for research, clinical, and business work like finding biomarkers, designing trial plans, and studying markets. These AI agents use several types of data like health records, gene info, and images to support quicker medicine research and cancer studies.
This multi-agent setup lets AI break down hard tasks into smaller ones, manage them instantly, and show clear progress during work. For clinical admins, AI helps keep trials on time by making sure every step, from finding patients to submitting documents, happens without mistakes or delays.
These AI systems also include controls for data safety and rule-following, which is very important in healthcare to protect patient privacy. This matters a lot in U.S. healthcare where rules like HIPAA apply.
Medical admins and IT managers often have to handle a lot of clinical trial data and workflows while keeping within the rules and saving money. Agentic AI can help in these ways:
IT managers need to connect AI solutions like those from IQVIA or AWS with current systems and keep data safe. These AI tools are built to work smoothly with common healthcare software like electronic health records and trial management programs.
Using AI for automating clinical trial workflows is changing healthcare teams’ roles and raising efficiency. Agentic AI manages trials through AI agents working together inside healthcare systems.
Key workflow improvements include:
These changes not only speed trials but also cut costs and improve patient experience during studies.
As agentic AI use grows, medical practice admins and IT managers should think about these points to use AI-driven clinical trial workflows well:
Medical practice administrators, healthcare owners, and IT managers in the United States can use agentic AI to improve clinical trial processes and decisions. Using these AI tools needs careful planning, managing data well, and training staff. But doing so can bring real gains in efficiency, rule-following, and patient care that fit with goals of modern healthcare systems.
IQVIA’s new AI agents, developed with NVIDIA technology, are designed to enhance workflows and accelerate insights specifically for life sciences, helping streamline clinical research, simplify operations, and improve patient outcomes across various stages like target identification, clinical data review, literature review, and healthcare professional engagement.
IQVIA uses NVIDIA’s NIM Agent Blueprints for rapid development, NeMo Customizer for fine-tuning AI models, and NeMo Guardrails to ensure safe deployment. This collaboration enables customized agentic AI workflows that meet the unique needs of the life sciences industry.
Agentic AI provides precision, efficiency, and speed in critical workflows such as planning clinical trials, reviewing literature, and commercial launches, allowing life sciences companies to gain actionable insights faster and improve decision-making.
Use cases include target identification for drug development, clinical data review, literature review, market assessment, and enhanced engagement with healthcare professionals (HCPs), which collectively improve research and commercial processes.
IQVIA integrates deep life sciences and healthcare domain expertise with advanced AI technology to deliver highly relevant, accurate, and compliant AI-powered solutions tailored to the industry’s complex workflows.
IQVIA employs a variety of privacy-enhancing technologies and safeguards, adhering to stringent regulatory requirements to protect individual patient privacy while enabling large-scale data analysis for improved health outcomes.
Healthcare-grade AI® by IQVIA is specifically built for the precision, speed, trust, and regulatory compliance needed in life sciences, facilitating high-quality actionable insights throughout the clinical asset lifecycle.
AI agents accelerate clinical trials by efficiently sifting through vast literature, identifying relevant data, coordinating workflow stages from discovery to commercial application, and reducing time-consuming manual tasks.
The partnership accelerates the development of customized foundation models and agentic AI workflows to enhance clinical development and access to new treatments, pushing the future of life sciences research and commercialization.
IQVIA TechIQ 2025, a two-day conference in London, will feature thought leaders including NVIDIA, exploring strategic approaches to AI implementation in life sciences to navigate the evolving frontier of healthcare AI applications.